Gelteq (GELS) Cash from Discontinued Operations (2023 - 2025)
Gelteq's (GELS) quarterly Cash from Discontinued Operations came in at 700577.26 in Q4 2025, up 70.04% year-on-year from 411996.38 in Q4 2024, and up 70.04% quarter-over-quarter from 2338727.98 in Q4 2024.
Gelteq (GELS) Cash from Discontinued Operations (2023 - 2025) Analysis & Trends
Gelteq's Cash from Discontinued Operations history runs 3 years deep, the most recent figure standing at 700577.26 for Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.88 Bn | 87.01 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.31 Bn | 30.37 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.27 Bn | 18.47 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.92 Bn | 16.61 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | - |
| 10 | Gelteq | 682.50 | -47,879.14 | - | -700,577.26 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -700,577.26 |
| Dec 31, 2025 | -700,577.26 |
| Dec 31, 2024 | -2.34 Mn |
| Dec 31, 2024 | -2.34 Mn |
| Dec 31, 2023 | -279,298.35 |
| Dec 31, 2023 | -279,298.35 |